Director Appointment

RNS Number : 1750A
OptiBiotix Health PLC
10 September 2018
 

OptiBiotix Health plc

("OptiBiotix")

 

Director Appointment

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol and diabetes, announces that, further to the previous announcement made on 6 August 2018 regarding the proposed appointment of Sean Christie as Non-Executive Director of the Company, the regulatory due diligence process has now been completed and the text below sets out the required disclosures.

 

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Michael Sean Christie (aged 60):

 

Current Appointments

Appointments in the last 5 years

ACCSYS Technologies Plc

Croda Enterprises Limited

Applied Graphene Materials Plc

Croda Europe Limited

Turner & Townsend Limited

Croda International Plc

 

Croda Investments Limited

 

Croda Investments No 2 Limited

 

Croda JDH Limited

 

Croda Overseas Holdings Limited

 

Croda Polymers International Limited

 

Croda World Traders Limited

 

Eminate Limited

 

Produce Investments Limited

 

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti


 

finnCap (Broker)

 

Tel: 020 7220 0500

Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)


Camille Gochez (Corporate Broking)




Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUGURGBUPRGCM
UK 100

Latest directors dealings